logo
Century-old shipwreck in North Sea is filled with stash of rare oysters in bid to revive marine species

Century-old shipwreck in North Sea is filled with stash of rare oysters in bid to revive marine species

CBS News21-07-2025
A cargo ship lying at the bottom of the sea off the Belgian coast has been fitted with a new treasure chest: a stash of rare flat oysters.
Molluscs have mostly disappeared from the North Sea due to human activity, including overfishing.
Now, a Belgian project is trying to reintroduce it in a move scientists believe will help boost other marine species.
"We have to bring them back because they are essential elements in our marine ecosystems," Vicky Stratigaki, an engineer working on the restoration project, told AFP.
In mid-July, a load of 200,000 oyster larvae attached to biodegradable materials was deposited about 100 feet under the sea in the ship's hull.
The environmental project, named Belreefs, aims to turn the wreckage into a biodiversity sanctuary.
Flat oysters form reefs that purify water and that other sea animals, from fish to algae, use as breeding and feeding grounds, explained Stratigaki.
"There is a lot of predation in the sea, it's a wild environment," she said, with about 30,000 of the oyster larvae expected to survive their first year at sea. "Then they will start reproducing, extending the reef and also supporting the biodiversity of the reef."
The laying of the oyster stash is the culmination of two years' work for the Belgian government project, which is supported by European Union funding.
"Until around the 1850s, the North Sea and the European waters were full of these oyster reefs," Stratigaki explained.
Then overfishing, the spreading of an imported parasite called Bonamia and "climatic adverse effects" caused them to disappear, she said.
The 1906 wreckage, located about 20 miles off the coastal city of Ostend, was selected to house the pilot as fishing and other disruptive activities are banned around it.
"In Belgium every wreck that is for more than one hundred years on the sea bottom gets protected automatically as cultural heritage, because it's nice for divers to go there," said Merel Oeyen, a marine environment expert at the Belgian ministry of health. "It's also a hot spot for biodiversity."
A 2023 paper published in BioScience found that shipwrecks provide important ecological resources for a wide variety of organisms, from tiny microbes to large marine creatures.
"Small fish and mobile crustaceans often find shelter in the crevices of the sunken material, and larger baitfish and predators use shipwrecks as feeding grounds and rest stops as they swim from one place to another," according to NOAA, which helped conduct the study.
However, scientists also warned shipwreck can also cause damage to existing marine life in the area, or carry harmful cargo, such as oil.
Still, the study's author, Avery Paxton, said shipwrecks can have "second lives" as homes to a variety of marine life.
"A ship's transformation from an in-service vessel into a thriving metropolis for marine life has a fairy-tale quality to it," Paxton said in an article published by the Washington Post after the study was released.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry

Yahoo

time2 hours ago

  • Yahoo

Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry

Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 19.7 billion by 2034. Market expansion is being fueled by a growing focus on biologics and biosimilars, particularly as the pharmaceutical industry shifts toward personalized therapies and precision medicine. The surge in demand for monoclonal antibodies, vaccines, and recombinant proteins has placed strong emphasis on the development of highly stable and productive cell lines. The increase in chronic illnesses-such as autoimmune diseases, cancer, and infectious disorders-has led to the rising adoption of biologics, which depend heavily on well-characterized cell lines. This has also elevated the need for quality-controlled production systems. Contract development and manufacturing organizations (CDMOs) have contributed significantly to market momentum. Small and mid-sized biotech firms are increasingly outsourcing their cell line development to CDMOs to reduce overhead costs and accelerate timelines, benefiting from their technical expertise, scalable platforms, and regulatory compliance with agencies like the FDA. This trend allows companies to focus on core competencies such as research and innovation while leveraging CDMOs for end-to-end services including cell line screening, clone selection, process optimization, and GMP manufacturing. These partnerships also offer access to advanced technologies, streamlined workflows, and proven quality assurance frameworks, enabling faster entry into clinical trials and reducing risks associated with internal capacity limitations. The reagents and media segment generated USD 3.4 billion in 2024. This segment continues to dominate due to its central role in cell growth and maintenance across both R&D and production stages. With a notable increase in the use of mammalian cells for biologics manufacturing, the demand for high-efficiency reagents and cell culture media has surged. A growing preference for protein-free and serum-free media is helping the segment gain traction, offering improved scalability, reduced risk of contamination, and consistency in large-scale production environments. Such media types are essential for regulatory approval and efficiency in biologics manufacturing, which demands stringent process control. In terms of cell type, the mammalian cells segment generated the highest revenue in 2024, accounting for 71.4%. Their dominance is linked to their superior ability to express human-compatible therapeutic proteins with accurate post-translational modifications. Widely used cell lines such as CHO and HEK-293 are favored in biologics production due to their robust protein folding, glycosylation, and scalability. Technological progress in gene editing tools, such as CRISPR-Cas9, combined with automation and high-throughput systems, continues to enhance the speed and stability of mammalian cell line development, further reinforcing their leadership in the market. The United States Cell Line Development Market was valued at USD 2.6 billion in 2024, driven by a combination of advanced biopharma infrastructure, high rates of chronic disease, and strong adoption of cutting-edge biologic therapies. The country's well-established pharmaceutical ecosystem, which includes top-tier biotech firms and extensive R&D investment, plays a pivotal role in expanding the market. Research institutions and innovation hubs across the US are also accelerating technological advancements in gene editing and automated platforms, leading to faster and more efficient development cycles. Government and private sector funding are also propelling innovation, further supporting the country's leadership in the field. Key companies operating in the Global Cell Line Development Market include PromoCell, Novartis, Genscript Biotech, Sartorius, Thermo Fisher Scientific, ProBioGen, Cytiva (Danaher Corporation), ASIMOV, Advanced Instruments, Sigma Aldrich (Merck KGaA), Eurofins Scientific, WuXi AppTec, Aragen Life Sciences, Fyonibio, and Lonza Group. Top-tier players in the cell line development space are heavily investing in technological innovations like automated cell screening platforms, single-use bioreactors, and CRISPR-based genome editing. Many companies are forming strategic alliances with biotech firms and CDMOs to enhance service offerings and expand production capabilities. Acquisitions are also a popular move to integrate novel technologies or gain regional access. Firms are focusing on R&D to develop serum-free and chemically defined media, helping improve regulatory compliance and scalability. Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 145 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $7.5 Billion Forecasted Market Value (USD) by 2034 $19.7 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics CoveredChapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 synopsis2.2 Key market trends2.2.1 Regional2.2.2 Products & services2.2.3 Source2.2.4 Cell line2.2.5 Application2.2.6 End use2.3 CXO perspectives: Strategic imperatives2.3.1 Key decision points for industry executives2.3.2 Critical success factors for market players2.4 Future outlook and strategic recommendationsChapter 3 Industry Insights3.1 Industry ecosystem analysis3.1.1 Supplier landscape3.1.2 Value addition at each stage3.1.3 Factors affecting the value chain3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing vaccine production worldwide3.2.1.2 Increasing prevalence of cancer across the globe3.2.1.3 Technological innovations in cell line development3.2.1.4 Growing biotechnology industry3.2.2 Industry pitfalls and challenges3.2.2.1 Complex regulatory landscape3.2.2.2 Challenges related to stem cell research3.2.3 Market opportunities3.2.3.1 Emerging applications in personalized medicine and regenerative therapies3.2.3.2 Adoption of artificial intelligence in cell line optimization3.3 Growth potential analysis3.4 Regulatory landscape3.4.1 North America3.4.2 Europe3.4.3 Asia Pacific3.4.4 Latin America3.4.5 Middle East and Africa3.5 Future market trends3.6 Emerging therapeutic applications of CHO cell lines3.7 Technology landscape3.7.1 Current technological trends3.7.2 Emerging technologies3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Key developments4.6.1 Merger and acquisition4.6.2 Partnership and collaboration4.6.3 New product launches4.6.4 Expansion plansChapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2034 ($ Mn)5.1 Key trends5.2 Reagents and media5.3 Equipment5.3.1 Incubator5.3.2 Centrifuges5.3.3 Bioreactors5.3.4 Storage equipment5.3.5 Microscopes5.3.6 Electroporators5.3.7 Fluorescence-activated cell sorting5.3.8 Other equipment5.4 Accessories and consumables5.5 ServicesChapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)6.1 Key trends6.2 Mammalian6.2.1 Chinese Hamster Ovary (CHO)6.2.2 Human Embryonic Kidney (HEK)6.2.3 Baby Hamster Kidney (BHK)6.2.4 Murine myeloma6.2.5 Other mammalian sources6.3 Non-mammalian6.3.1 Insects6.3.2 AmphibiansChapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2034 ($ Mn)7.1 Key trends7.2 Recombinant7.3 Hybridomas7.4 Continuous cell lines7.5 Primary cell linesChapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)8.1 Key trends8.2 Bioproduction8.3 Drug discovery8.4 Toxicity testing8.5 Tissue engineering8.6 ResearchChapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)9.1 Key trends9.2 Pharmaceutical and biotechnology companies9.3 Academic and research institutes9.4 Contract research organizations (CROs)Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)10.1 Key trends10.2 North America10.2.1 U.S.10.2.2 Canada10.3 Europe10.3.1 Germany10.3.2 UK10.3.3 France10.3.4 Italy10.3.5 Spain10.3.6 Netherlands10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 India10.4.4 Australia10.4.5 South Korea10.5 Latin America10.5.1 Brazil10.5.2 Mexico10.6 Middle East and Africa10.6.1 South Africa10.6.2 Saudi Arabia10.6.3 UAEChapter 11 Company Profiles11.1 Advanced Instruments11.2 Aragen Life Sciences11.3 ASIMOV11.4 Cytiva (Danaher Corporation)11.5 Eurofins Scientific11.6 Fyonibio11.7 Genscript Biotech11.8 Lonza Group11.9 Novartis11.10 ProBioGen11.11 PromoCell11.12 Sartorius11.13 Sigma Aldrich (Merck KGaA)11.14 Thermo Fisher Scientific11.15 WuXi AppTecFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Line Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Type II Vasculitis Signals Poor Prognosis in Sjögren Disease
Type II Vasculitis Signals Poor Prognosis in Sjögren Disease

Medscape

time4 hours ago

  • Medscape

Type II Vasculitis Signals Poor Prognosis in Sjögren Disease

TOPLINE: Among patients with primary Sjögren disease, type II cryoglobulinemic vasculitis is linked to an increased risk for lymphoma and mortality, a French study showed. METHODOLOGY: Researchers conducted a retrospective multicenter cohort study of 54 patients with primary Sjögren disease and cutaneous vasculitis (CV) from three pathology departments in Paris and a national case call in France (median age, 42 years; 91% women). Patients were diagnosed with CV between 2011 and 2021; 29 (57%) had cryoglobulinemic vasculitis and 15 (28%) had hypergammaglobulinemic vasculitis; 24 of the 29 cryoglobulinemic cases were type II. Data were analyzed between March 2023 and March 2025. Patients were matched 1:2 to 108 controls with Sjögren disease but without CV from the French ASSESS cohort. Primary outcomes of the study were the occurrence of lymphoma diagnosis and mortality risk. TAKEAWAY: Patients with Sjögren disease and CV showed a higher lymphoma incidence than those without CV (13% vs 4%; P = .04). Patients with type II cryoglobulinemic vasculitis had a significantly higher incidence of lymphoma (21% vs 0%; P = .02) and increased mortality (29% vs 0; P = .02) than those with other types of small-vessel vasculitis. The risk for death or non-Hodgkin lymphoma was increased by nearly sevenfold risk in patients with type II cryoglobulinemic vasculitis (hazard ratio [HR], 6.8; P = .005) compared with other CV types. Patients with type II cryoglobulinemic vasculitis were more likely to have subacute cutaneous lupus (21% vs 0%; P = .02), kidney involvement (29% vs 4%; P = .02) and peripheral nervous system involvement (63% vs 12%; P < .001) than those with other CV types. Among 24 patients with type II cryoglobulinemic vasculitis, 12 received rituximab-based first-line treatment; non-Hodgkin lymphoma developed in 8% of patients in the rituximab group and in 25% of those who received other treatments, whereas mortality rates were 33% and 25%, respectively. IN PRACTICE: 'In this cohort study, among patients with CV-complicated Sjögren disease, only type II cryoglobulinemic vasculitis was associated with severe visceral involvement, higher risk of non-Hodgkin lymphoma, and mortality,' the study authors wrote. These findings, they added, highlighted the need for 'specific monitoring for these patients.' SOURCE: The study was led by Paul Breillat, MD, INSERM, Paris Centre de Recherche Cardiovasculaire, Paris, France, and was published online on August 6 in JAMA Dermatology. LIMITATIONS: The retrospective design and potential missing data could affect the interpretation of results. Additionally, half of the patients were diagnosed with CV on the basis of clinical criteria. DISCLOSURES: The ASSESS cohort was set up with a grant from the French Ministry of Health. One author reported receiving personal fees from Bristol Myers Squibb, GSK, Novartis, and Otsuka; another author reported receiving grants from AstraZeneca, Bristol Myers Squibb, and GSK. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store